Cargando…
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive ‘mid-size’ Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in oncology...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838869/ https://www.ncbi.nlm.nih.gov/pubmed/29506529 http://dx.doi.org/10.1186/s13046-018-0702-x |